MSLN and neoplasm: In mesothelioma xenograft models, mesothelin-targeted TRuC (TC-210) T cells showed a more rapid reduction in tumor volume, enhanced infiltration into tumors, and faster activation and greater persistence in the tumor microenvironment compared to mesothelin-targeted CAR T cells [21].